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Abstract: There is emerging evidence which indicates the essential role of genetic factors in the development of diabetic 
retinopathy (DR). In this regard it should be highlighted that genetic factors account for 25-50% of the risk of developing 
DR. Therefore, the use of genetic analysis to identify those diabetic patients most prone to developing DR might be useful 
in designing a more individualized treatment. In this regard, there are three main research strategies: candidate gene stud-
ies, linkage studies and Genome-Wide Association Studies (GWAS). In the candidate gene approach, several genes en-
coding proteins closely related to DR development have been analyzed. The linkage studies analyze shared alleles among 
family members with DR under the assumption that these predispose to a more aggressive development of DR. Finally, 
Genome-Wide Association Studies (GWAS) are a new tool involving a massive evaluation of single nucleotide polymor-
phisms (SNP) in large samples. In this review the available information using these three methodologies is critically ana-
lyzed. A genetic approach in order to identify new candidates in the pathogenesis of DR would permit us to design more 
targeted therapeutic strategies in order to decrease this devastating complication of diabetes. Basic researchers, ophthal-
mologists, diabetologists and geneticists should work together in order to gain new insights into this issue. 
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INTRODUCTION 
 Diabetic retinopathy (DR) is the main cause of blindness 
in working-age adults in developed countries. It is well 
known that diabetes duration, poor glycemic control, and 
hypertension are the primary factors accounting for the risk 
of developing DR [1-13]. Therefore, the available tools to 
prevent this disease are a tight control of both blood glucose 
levels and hypertension, as well as the implementation of the 
current screening guidelines. Clinical studies on human sub-
jects with diabetes reveal a substantial variation in the onset 
and severity of retinopathy that is not fully explained by the 
known risk factors [14-17]. Indeed, in the ADVANCE Trial 
intensive glucose control to reduce glycosylated hemoglobin 
to 6.5% or lower had no effect on the 5-year incidence of DR 
[16]. In the same study, the lowering of blood pressure to 
near normal levels did not achieve a further reduction in the 
progression of DR [16]. In addition, some patients with poor 
control of glycemia or blood pressure do not develop DR 
[17]. These data suggest that genetic factors play an essential 
role in accounting for the susceptibility to developing this 
late diabetic complication. 
 Genetic factors may influence either the onset or the se-
verity of DR. In fact, heritability estimates ranging from 
25% to 50% have been reported for proliferative DR [18, 
19]. Also the study of identical twins found a concordance 
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for DR (68% in type 1 diabetes and 95% in type 2) [20] and 
in the Diabetes Control and Complication Trial cohort, the 
odds ratio for severe retinopathy when a relative had reti-
nopathy was 3.1 [15]. Similar findings have been replicated 
in other familial risk studies [21-23]. 
 Genetic susceptibility to retinopathy is also suggested by 
the findings in some studies of a greater prevalence of reti-
nopathy among certain ethnic groups. In the Veterans Affairs 
Diabetes Trial, the prevalence of moderate to severe DR was 
found to be higher for Hispanics and African-Americans 
than for non-Hispanic whites [24]. However, ethnicity did 
not explain the difference in the prevalence of DR in another 
large study [25]. 
 With the study of the genetics of this disease we will be 
able to identify genome variants that are associated with an 
increased risk of complications among diabetic subjects, 
with the expectation that the location and function of these 
variants will point to genes and hence molecular pathways 
that are involved in the etiology of DR. Such genetic ap-
proach may also generate algorithms for the early identifica-
tion of diabetic individuals at a high risk of complications 
who may benefit from especially aggressive prevention pro-
grams. In this regard there are three main research strategies, 
namely; candidate genes studies, linkage studies in families 
and Genome-Wide Association Studies (GWAS). 
Method of Literature Review 
 References for this review were identified through a 
comprehensive literature search of the electronic MEDLINE 
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database (2000-2013) using the PubMed search service. 
Search terms included: diabetic retinopathy, genetics, genes, 
Genome-Wide Association Studies, linkage studies. The 
search was conducted in January-April 2013 and all abstracts 
were reviewed and relevant articles retrieved. In addition, 
reference lists from the selected articles were used to obtain 
further articles not included in the electronic database. 
Candidate Genes Studies 
 In the candidate gene approach, several genes encoding 
proteins closely related to DR are analyzed, usually in case-
control studies. Most candidate gene studies have examined 
the genetic variants implicated in diabetes development or 
metabolic pathways such as the polyol pathway, the forma-
tion of advanced glycation end products (AGE) and hypoxia 
induced angiogenesis through vascular endothelial growth 
factor (VEGF). 
 These kinds of studies are usually based on small patient 
samples, and they often yield inconsistent results. To cir-
cumvent this issue, meta-analyses have been undertaken to 
pinpoint the few genes for which there might be cumulative 
evidence for an association with DR.  
Aldose Reductase Gene 
 The polyol pathway is a major metabolic pathway linking 
hyperglycemia to diabetic complications, and aldose reduc-
tase (ALR2) is the first and rate limiting enzyme of this 
pathway. ALR2 converts glucose to sorbitol in an NADPH-
dependent reaction. Hyperglycemia leads to intracellular 
sorbitol accumulation, thus resulting in osmotic stress, which 
plays an essential role in the development of diabetic reti-
nopathy [26].  
 The gene encoding ALR2 is located on chromosome 
7q35, and a meta-analysis has found that the ALR gene 
(AKR1B1) is the most significantly associated with DR [27]. 
Associations of three ALR2 SNPs (single nucleotide 
polymorphisms) with DR have been reported in the 
literature: the promoter SNP rs759853, the (CA)n 
microsatellite polymorphism located at 5’ of the ALR gene, 
and more recently, SNP rs9640883. However, it has been 
suggested that the commonly reported association of 
AKR1B1 with DR may be due to an association of this 
polymorphism with a younger age at the onset of diabetes 
rather than its direct effect on DR development [28]. 
 Three alleles of (CA)n microsatellite have been related to 
DR. A significant association with z-2 allele and DR (both 
non-proliferative and proliferative DR) has been found in 
type 1 and type 2 diabetes. By contrast, the z+2 allele has 
been reported as protective against the development of DR 
[27, 29]. In addition, a T allele of the promoter SNP 
rs759853 also seems to confer protection against DR devel-
opment. Finally, it has been found that SNP rs9640883 is 
associated with DR but, as occurs with AKR1B1, this asso-
ciation may reflect the effect that this gene has on the age of 
onset of diabetes and, therefore, on diabetes duration, rather 
than a direct effect on increasing the risk of DR [27].  
VEGF 
 Vascular endothelial growth factor (VEGF), it is an endo-
thelial cell-specific mitogen and has been implicated as a 
major contributor to the development of DR [30, 31]. Both 
hypoxia and hyperglycemia stimulate VEGF expression, and 
in consequence elevated VEGF and its receptor expression 
have been demonstrated in diabetic retinas [30-33].  
 The VEGF gene is located in chromosome 6 (6p21.3). 
Many SNP’s have been associated with DR, most of them 
located in the promoter region of the gene [34]. The most 
important one is the +405 genotype, which has been impli-
cated in a number of diseases, in particular those with an 
angiogenic basis, like DR. Several studies conducted in the 
Japanese population have demonstrated an association be-
tween the +405 CC genotype or the C allele and the presence 
of DR [35-37]. However, this association has not been con-
firmed in Caucasian population [38]. Interestingly, it has 
been demonstrated that the C allele is associated not only 
with higher serum levels of VEGF [34] but also with a 
higher expression of VEGFA in the human retina [39]. In 
addition, it has also been associated with an increased risk of 
developing diabetic macular edema [35]. On the other hand, 
the GG genotype of this polymorphism (compared with the 
CC genotype) has been found to be an independent predictor 
of PDR in other studies performed in Caucasian population 
[40, 41]. Finally, through Indian population, the CG geno-
type has been associated with DR [42, 43]. Nonetheless, a 
meta-analysis considering the G allele the risk variant, did 
not find any statistically significant association between this 
polymorphism and DR [28].  
 In a Caucasian population, Bleda et al. [41] found a rela-
tion between the CA genotype of the -2578 polymorphism, 
which is located in the promoter region of the VEGF gene, 
and a susceptibility to developing DR. However, this result 
has not been confirmed in other studies [28, 44]. Also in a 
Caucasian population, Carter et al. [45] found an association 
between PDR and the SRp55 2994 polymorphism, which is 
one of the splicing factors that control alternative splicing of 
the last exon of VEGF pre-RNA, a key element in the bal-
ance of pro- and anti-angiogenic VEGF isoforms.  
 While individual SNPs showed modest associations with 
DR, multiple VEGFA variants, assessed by a multi-SNP test, 
were associated with the development of severe DR in Cau-
casian type 1 diabetic patients from the Diabetes Control and 
Complications Trial (DCCT)/Epidemiology of Diabetes In-
terventions and Complications (EDIC) [46]. Further research 
to confirm this finding is necessary.  
Receptor for Advanced Glycation End Products Gene 
(RAGE) 
 Advanced glycation end products (AGEs) result from the 
non-enzymatic glycation of proteins and lipids caused by 
hyperglycemia. It has been suggested that AGEs accumula-
tion contributes to diabetic complications through direct tis-
sue damage, as well as through activating specific receptors 
for AGE (RAGE)[47-49]. The role of RAGE (a member of 
the immunoglobulin superfamily located in chromosome 
6p21.3) in the pathophysiology of DR, makes its polymor-
phisms good candidates for influencing DR development.  
 The -374A T/A polymorphism influences a transcription 
factor-binding site which, in turn, leads to the upregulation 
of RAGE transcription. Some studies have found an associa-
tion between the -374 T/A polymorphism and sight-threatening
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Table 1. Main Studies on Candidate Genes Related to Diabetic Retinopathy 
Genes Polymorphisms OR p n Population Type of 
Study 
TDM Special Features Reference 
rs759853 T allele 0.49 0.0001 2207 - Meta-
analysis 
1 and 2 Protection against DR in type 1 diabetes. [27] 
z-2 allele 2.33 0.0002 1973 - Meta-
analysis 
1 and 2 Weaker association in type 1 diabetes 
than type 2 diabetes. 





z+2 allele 0.58 0.02 1693 - Meta-
analysis 
1 and 2 Protective effect. 




rs9640883 1.62 0.0005 514 Australian Case-
control 
1 and 2  [25] 
3.2 0.004 452 Japanese Case-
control 
2 VEGF serum levels are higher in 
healthy subjects with the CC genotype. 
[33] CC 
genotype 
- NS 919 Caucasian Case-
control 
2 No statistical association with DN. [34] 
1.87 0.039 398 Iranian Case-
control 
2 The polymorphism increases the risk of 
PDR vs NPDR. 
[35] GG 
genotype 
- NS 919 Caucasian Case-
control 
2 No statistical association with DN. [34] 
2.3 0.008 210 Indian Case-
control 
2 Case group: patients with PDR. [40] CG 
genotype 
1.66 0.42 213 South Indian Case-
control 
2 The distribution of this genotype was 
significantly higher in patients with DR 
and microalbuminuria than in those 
patients with microalbuminuria but 
without DR. 
[43] 
G allele 0.62 0.0005 4226 - Meta-
analysis 
2 Significant association in patients with 






- NS 469 Japanese Case-
control 
2  [44] 
AA 
genotype 
7.5 (Rm) 0.002 469 Japanese Case-
control 





- 0.002 40 Caucasian Case-
control 
2 CC genotype may be associated with 
susceptibility to diabetic PAD while the 
CA genotype may be associated with 
susceptibility to DR. 
[36] 
VEGF 
SRp55 2994 2.1 0.030 258 Caucasian Case-
control 









1 and 2 The frequency of the A allele was 
higher in patients with sight-threatening 
DR. 
[50] 
1.814 0.048 528 South India Case-
control 
2 Modest association with NPDR. [51] 
RAGE -374A T/A 
- NS 577 Malaysian Case-
control 
2  [52] 
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(Table 1) contd…. 
Genes Polymorphisms OR p n Population Type of 
Study 
TDM Special Features Reference 





2  [53] 
- NS 669 Chinese Case-
control 
2  [54] 
0.76 NS 704 Indian Case-
control 
2 Significant association between SNP 
rs2070600 of RAGE gene and DR. 
[56] 
 





1 and 2  [61] 
2.964 0.029 688 Chinese Case-
control 
2  [57] 
- NS 210 Indian Case-
control 
2  [59] 
- NS 3049 Asian Meta-
analysis 
2  [60] 
Gly82Ser 





1 and 2  [61] 




2  [60] -429 T/C 





1 and 2  [61] 
2245G/A.   A allele 3.06 <0.001 577 Malaysian Case-
control 
2 Both NPDR and PDR. [62] 




2  [60] 
 
1704G/T.    T allele 





1 and 2 Subgroup analysis by ethnicity indi-
cated that allele 1704T conferred a 
signi cant increase of risk in East 
Asians but not in Caucasians. 
[61] 
2.4 0.013 575 West African Case-
control 
2  [65] 




2  [67] 
- NS 3377 - Meta-
analysis 
1 and 2  [27] 
4 a/b polymorphism bb 
genotype 




Most 2 Protective effect. 
No statistical association was found in 
the dominant, recessive or co-dominant 
models. 
No statistical was found after the 
stratification for ethnicity. 
[69] 
NOS3 
C allele of T786C 3.4 <0.001 249 Caucasian Case-
control 
1 They also found a significant associa-
tion with diabetes. 
[68] 
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(Table 1) contd…. 
Genes Polymorphisms OR p n Population Type of 
Study 
TDM Special Features Reference 




2  [67]  




Most 2  [69] 
 
G894T - NS 2819 Most Cauca-
sian and Asian 
Meta-
analysis 




1.831 0.026 384 Iranian Case-
control 
2  [71] 
3.516 0.015 136 Iranian Case-
control 





















Subgroup analyses based on the type of 
DR showed that the effect was signifi-
cant for PDR but not NPDR. 
[73] 
ACE 
2350 G/A   AA geno-
type 
4.4887 0.0006 235 Han Chinese Case-
control 
2  [74] 
TDM (type of diabetes mellitus), DR (diabetic retinopathy), PDR (proliferative diabetic retinopathy), NPDR (non-proliferative diabetic retinopathy), DN (diabetic nephropathy), PAD 
(peripheral arterial disease), Rm (recessive model). 
DR [50, 51]. However, these findings have not been sup-
ported by other studies [52-56].  
 Gly82Ser and -429 T/C polymorphisms may also in-
crease the risk of DR in some populations [56-58], although 
this relationship has not been significant in other studies [51, 
52, 54, 55, 59].  
 Two meta-analysis performed in Caucasian and Asian 
populations [60, 61], did not found a significant association 
between these polymorphisms (-374A, Gly82Ser and -429 
T/C) and DR. Interestingly, the meta-analysis in which East 
Asian subjects were the predominant population, the 1704T 
allele was associated with an increased risk of DR [61]. 
Moreover, recently, it has been reported in a Malaysian 
population that the 2245A allele is associated with the de-
velopment of DR [62]. Further studies are necessary to cor-
roborate these findings. 
Endothelial Nitric Oxide Synthase (eNOS) 
 eNOS catalyses the formation of the molecule NO from 
the substrate L-arginine [63], and has been implicated in the 
pathogenesis of diabetic vascular complications. For in-
stance, diabetic eNOS(-/-) mice exhibit a significantly wider 
range of advanced retinal vascular complications [64]. The 
eNOS gene (NOS) is located in chromosome 7q35-26, and 
its polymorphisms have been related to an increase in the 
risk of developing DR [28].  
 The a/b polymorphism of the intron 4 eNOS gene was 
found to have a significant association with DR in a West 
African cohort [65]. However, more recent studies, including 
a meta-analysis, have not found a significant association 
between this polymorphism and the early onset of mycroan-
giopathy [66, 67]. Similarly, the C allele of T-786C poly-
morphism was initially associated with DR [68] but this has 
not been confirmed by other studies [28, 65, 67].  
 Recently, Zhao et al. [69] conducted a meta-analysis in 
which the association of those aforementioned polymorphisms 
was analyzed. A significant association was found between 
the intron 4a allele of the 4b/a polymorphism and a reduced 
risk of DR. The C allele of T-786C polymorphism may be a 
protective factor for PDR. In addition, they could not prove an 
association between the G894T polymorphism and DR. 
Angiotensin-I Converting Enzyme (ACE) 
 The ACE gene, which is located in 17q23 chromosome 
[28], is one of the most studied candidate genes. ACE is part 
of the renin-angiotensin system and has been implicated in 
the development of DR. In fact, elevated ACE expression 
has been shown to have an adverse effect on retinal blood 
flow and vascular structure and it also promotes the forma-
tion of new retinal blood vessels [70]. 
 The insertion/deletion (I/D) polymorphism has been one 
of the most investigated and has been associated with DR 
[71, 72]. A recent meta-analyses in which more than two 
thousand Chinese patients were included showed that the I/D 
polymorphism was associated with PDR, but not with non-
proliferative DR [73]. 
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 Finally, the ACE 2350 G/A polymorphism, which among 
the polymorphisms of this gene is known to have the most 
significant effect on plasma ACE concentrations, has been 
associated with DR in Han Chinese patients with type 2 dia-
betes [74].  
Others 
 The erythropoietin (EPO) gene is located on 7q21 and 
encodes an angiogenic factor expressed in the retina and the 
kidney. There is a well documented association between 
PDR and diabetic nephropathy, and this could be explained 
by the existence of common genetic factors. Tong et al. [75] 
genotyped 19 SNPs from 11 candidate genes in diabetic pa-
tients with or without PDR and end-stage renal disease and 
tested for allelic associations. This study showed an associa-
tion between a functional EPO promoter polymorphism 
(rs1617640) and both eye and kidney diabetic microvascular 
complications in a European-American population. The risk 
allele (T) was associated with elevated EPO levels in the 
vitreous fluid [75]. These results were confirmed in a large 
case-control meta-analysis of diabetic nephropathy in type 1 
diabetic patients. However, no association was observed 
between the rs1617640 polymorphism and PDR when this 
microvascular complication was analyzed irrespective the 
renal failure [76]. It should be noted that EPO could play a 
neuroprotective role in the early stages of DR and it protects 
the retinal pigment epithelium against the increase of perme-
ability induced by diabetic conditions [77-79]. However, 
EPO acts synergistically with VEGF in advanced stages of 
DR, thus favouring angiogensis and PDR [80]. Therefore, 
further studies to clarify this double-edged sword role of 
EPO in the pathogenesis of DR are needed.  
 On the other hand, specific genetic loci that are associ-
ated with differences in HbA1c between people with type 1 
diabetes have been convincingly identified, and they have 
also been shown to be associated with diabetic complications 
[81].  
 Finally, a recent meta-analysis provides evidence that the 
Pro12Ala polymorphism of the peroxisome proliferator–
activated receptor- 2 (PPAR 2) is associated with DR. The 
Ala allele of the Pro12Ala polymorphism has a protective 
effect on the incidence of DR in Caucasian but not in Asian 
type 2 diabetic patients [82].  
Linkage Studies 
 Linkage studies analyze shared alleles among family 
members under the assumption that these predispose to a 
more aggressive development of DR. One of the earliest 
linkage studies was performed by studying the genome of 
identical twins with DR, and a concordance of 68% in type 1 
diabetes and 95% in type 2 diabetes was found [20], but in 
this study no specific genome regions were identified. Al-
most twenty years later a linkage analysis among Pima Indi-
ans with type 2 diabetes was performed to identify suscepti-
bility genes for both DR and nephropathy [83]. Two regions, 
one on chromosome 3 and one on chromosome 9 indicated a 
tentative linkage with retinopathy, although none of them 
was significant. It should be noted that a tentative linkage 
between a region relatively close to the angiotensine II re-
ceptor gene (AGTR1), which is located on chromosome 
3q2125, and both nephropathy and retinopathy was found in 
this study [83].  
 More recently, a genome-wide linkage analysis designed 
to identify loci for DR, taking into account the severity of the 
DR was also performed in a Pima Indian population. A mod-
est level of familial aggregation and suggestive evidence for 
linkage to chromosome 1p36 was found [84]. The genes lo-
cated in this region were: peptidyl arginine deiminases 
(PADI) 1, 2, 3, 4 and 6, CASP-9, CLCN-Ka and CLCN-Kb, 
and none of these genes had previously been associated with 
DR. The main weakness of this study was that only 4% of 
the cohort had moderate non-PDR or worse. This means that 
their observations were limited to relatively early stages of 
retinopathy and so may not have described genetic factors 
associated with more severe disease. Further linkage studies 
or candidate gene studies (with PADI, CASP-9, CLCN-Ka 
and CLCN-Kb) would be useful to confirm this association. 
The difference between these two studies into a Pima Indian 
population could be explained by the sample size and be-
cause diabetes duration and severity of DR were not consid-
ered in the first study.  
 Another linkage study was performed into a population 
of Mexican Americans but it did not reach the level of ge-
nome-wide significance for any gene [85]. The strongest 
evidence involved the proximal end of chromosome 12. Sev-
eral candidate genes potentially involved with DR occurred 
in this region such as WNT5B (associated with adipogenesis 
and type 2 diabetes), TULP3 (associated with retinal degen-
eration), GNB3, WNK1, SCNN1A (the last three associated 
with hypertension), ING4 (associated with angiogenesis) and 
OLR1 (associated with hypertensive vascular damage and 
involved in choroidal neovascularization in age-related 
macular degeneration). The next strongest evidence, al-
though without statistical significance occurred in chromo-
some 3 in which are located some genes related with retinal 
diseases such as ROBO2 (associated with retinal develop-
ment), PROS1 (associated with venous thrombosis and reti-
nopathy of prematurity), ARL6 (associated with Bardet-
Bield Syndrome with retinal dystrophy) and IMPG2 (associ-
ated with retinal interphotoreceptor matrix proteoglycan) 
[85].  
Genome-Wide Association Studies 
 Genome-Wide Association Studies (GWAS) involve the 
massive evaluation of SNPs in large samples, thus represent-
ing a new tool for identifying candidate genes. This is based 
on the genome-wide characterization of linkage disequilib-
rium, the phenomenon by which adjacent polymorphisms are 
correlated with each other because of their co-segregation 
from one generation to the next. Using these data, publicly 
available from the HapMap database, a set of SNPs can be 
selected that most efficiently capture the 10 million or so 
common polymorphisms in the human genome. In addition, 
technology based on microarrays is used and several hundred 
thousand selected SNPs can be typed in a single assay [86]. 
We will review the first steps in the genetics of DR with this 
unique approach. 
 The genome-wide meta-analysis association data for se-
vere DR in two large cohorts of type 1 diabetes (the Genetics 
of Kidney in Diabetes and the Epidemiology of Diabetes 
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Intervention and Control Trial studies) did not find any sig-
nificant genome-wide association. However, a relationship 
between the intergenic SNP rs476141 and the presence of 
severe DR was found. The intergenic SNP rs476141 is lo-
cated in a region between two genes, AKT3 and ZNF238. 
Interestingly, AKT3 is a serine/threonine kinase regulating 
cell survival, insulin signaling and angiogenesis, and has 
been shown to be activated by platelet-derived growth factor 
and insulin-like growth factor 1, which have both been im-
plicated in PDR [87]. This association was not replicated in a 
cohort of type 1 diabetic patients from the Wisconsin Epi-
demiologic Study of Diabetic Retinopathy but new genetic 
loci potentially associated with severe DR were identified 
[88]. The strongest association was at rs4865047, an intronic 
SNP in the gene CEP125. This gene is expressed in the ret-
ina and is related to TGF-  signaling. However, further stud-
ies to confirm these associations are needed. 
 The Candidate-gene Association Resource (CARe) was a 
collaborative study aimed at investigating the association 
analyses between genotypes and cardiovascular disease 
phenotypes [89]. It comprised >40,000 participants from 
nine cohorts who had been genotyped for 49,320 SNPs from 
approximately 2,000 candidate genes postulated or known to 
increase the risk of cardiovascular, metabolic, and 
inflammatory diseases [90]. It included 2691 type 2 diabetic 
subjects with fundus photographs of multiple ethnicities. 
Therefore, the CARe framework provided an opportunity to 
investigate genetic associations for DR with a candidate gene 
approach. In this regard it has recently been investigated 
whether variants in cardiovascular candidate genes, some of 
which have been previously associated with type 2 diabetes, 
DR, and diabetic nephropathy, are associated with DR in the 
CARe [91]. In this study three SNPs in the P-selectin (SELP) 
gene were associated with DR in the European American 
population but they were unable to replicate this finding in 
other ethnic groups. In this regard, it has been found that 
genetic effects identified by GWAS are not consistent across 
populations of different ancestry [92]. Therefore, genomic 
risk markers need a separate evaluation in different ethnic 
groups. 
 GWAS studies have some limitations. The commercial 
arrays used for GWA scans are designed to provide excellent 
coverage of common SNPs, but have only limited potential 
to capture rare and low frequency variants (i.e. those with a 
minor allele frequency below 5% [93]. Furthermore, if sus-
ceptibility alleles have minor allele frequencies of less than 
0.1 and their effect sizes are less than an odds ratio of 1.3, 
then unrealistically large sample sizes of more than 10,000 
cases and 10,000 controls (or 10,000 families) would be re-
quired to achieve statistical support for a disease association 
[94]. 
 Mild retinopathy, defined as the presence of isolated mi-
croaneurysms or dot-blot hemorrhages, is observed in 5 to 
15% of the general non-diabetic population [95]. Jensen et 
al. [96] conducted a GWAS to examine the association be-
tween 2.5 million SNPs and the presence of isolated mi-
croaneurysms or dot-blot hemorrhages in a non diabetic 
population. The results from this study showed little evi-
dence that the presence of mild retinopathy in individuals 
without diabetes was associated with SNPs. However, 
further studies are needed to explore the remaining highly 
suggestive SNPs such as rs12155400 (located in the histone 
deacetylase 9 gene [HDAC9] on chromosome 9 7). This may 
include fine mapping in HDAC9, gene-environment 
interaction studies or pathway analyses.  
CONCLUDING REMARKS 
 There have been extensive research efforts to understand 
the genetics of DR. The genetic associations of DR are use-
ful as a research tool but may also have a relevant clinical 
value in identifying patients at a high risk of developing RD. 
Thus, more frequent examinations of high-risk patients, and 
less frequent examinations of low-risk patients, may lead to 
the more efficient targeting of health care resources.  
 Heritability has been estimated to be as high as 27% for 
DR and 52% for PDR. Efforts to unravel the human genetics 
of DR have been undertaken using the candidate gene, link-
age approaches, and more recently GWAS. A large number 
of putative genes and genetic variants have been reported in 
the literature and some of them exhibit consistent associa-
tions with DR (ALR2, VEGF and RAGE genes). However, 
these results have not been replicated in multiple populations 
and, therefore, no genes have achieved widespread accep-
tance as conferring a high risk of DR. These inconsistencies 
may reflect the lack of an accurate definition of DR, the 
small subject numbers, underlying genetic differences be-
tween study populations, and differences in study design. In 
addition the duration of diabetes is a key factor which should 
be considered in the analysis of the results. Finally, the 
overlap of DR with ‘non-diabetic’ retinopathy, which has 
been found to occur in 5-15% of subjects without clinical 
diabetes, could also be a confounding factor. It is expected 
that GWAS will provide novel insights into genetic 
susceptibility to DR in the near future. Moreover, the 
genomic sequence data to be published in the near future will 
be useful to define genetic factors that confer a risk for the 
development and progression of DR. 
 In summary, a genetic approach in order to identify new 
candidates in the pathogenesis of DR would permit us to 
design more targeted therapeutic strategies in order to de-
crease this devastating complication of diabetes. Basic re-
searchers, ophthalmologists, diabetologists, and geneticists 
should work together in order to gain new insights into this 
issue.  
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